Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune...
-
SOUTH SAN FRANCISCO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated...
-
Consistent efficacy and safety profile for pemphigus patients observed Confirms 400mg twice daily dose in Phase 3 trial Principia to host investor conference call at 8:00 am Eastern time SOUTH...
-
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
-
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
-
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
-
SOUTH SAN FRANCISCO, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
-
SOUTH SAN FRANCISCO, Calif., June 11, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
-
-- FGFR inhibitor PRN1371 well tolerated in 36 patients in dose-escalation phase; dose expansion in metastatic urothelial carcinoma patients ongoing -- SOUTH SAN FRANCISCO, Calif., May 20, 2019 ...
-
SOUTH SAN FRANCISCO, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...